On March 26, 2025, the U.S. Food and Drug Administration (FDA) approved a generic version of ZTlido™. The first-of-its-kind generic lidocaine 1.8% patch is produced by Aveva Drug Delivery systems (a DifGen company), a leader in transdermal drug delivery systems based out of Miramar, Florida.
What are 1.8% lidocaine patches used for?
As a transdermal medication applied on top of the skin, the generic lidocaine patch:
- Provides patients suffering from localized nerve pain a more affordable, effective, and accessible treatment option.
- Uses a unique patch design that is bioequivalent to other lidocaine patches, such as Lidoderm® (lidocaine) 5% patch, with an adhesive that provides more consistent skin contact.
About ZTlido
Brand name ZTlido, a non-opioid topical treatment for post-herpetic neuralgia (PHN), is manufactured by Scilex Pharmacueticals. ZTlido is a non-hydrogel patch that delivers a local dose of lidocaine, offering relief directly at the site of pain. The generic version of ZTlido will offer a more cost-effective alternative of the same efficacy.
MyMatrixx Actions
While newly approved, the generic lidocaine 1.8% patch has not launched on the market. The MyMatrixx clinical team will continue to monitor for updates on the generic patch pricing.